YAKUGAKU ZASSHI
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 16,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Sumio Ohtsuki
Faculty of Life Sciences, Kumamoto University
Read more
17,724 registered articles
(updated on October 05, 2022)
Online ISSN : 1347-5231
Print ISSN : 0031-6903
ISSN-L : 0031-6903
0.314
2021 Journal Impact Factor (JIF)
JOURNAL PEER REVIEWED FREE ACCESS ADVANCE PUBLICATION
Scopus Pubmed
Featured article
Volume 142 (2022) Issue 10 Pages 1091-1101
Biased Signaling through G Protein-coupled Receptors Read more
Editor's pick

Biased agonists of GPCRs are agonists that selectively induce G protein- or β-arrestin-mediated responses. Biased agonists have become an important concept in drug discovery, as they are thought to result in drugs with fewer side effects. It should be noted, however, that the actions of G protein biased agonists can also be explained by the effects of partial agonists. In many cases, biased agonists bind to and exert their effects at different sites than endogenous agonists.

View all featured articles
Most viewed articles (September 2022)
Share this page
Browse by volume and issue
feedback
Top